Loading clinical trials...
Loading clinical trials...
Phase 3 study to examine treatment with ITCA 650 compared to glimepiride when added to metformin monotherapy in reducing HbA1c in patients with type 2 diabetes.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Intarcia Therapeutics
NCT07232537 · Chronic Kidney Disease, Type 2 Diabetes Mellitus
NCT06815081 · Type 1 Diabetes (T1D), Type 2 Diabetes
NCT06003153 · Genetic Predisposition, Metabolic Diseases, and more
NCT06278207 · Chronic Kidney Disease, Type 2 Diabetes Mellitus
NCT07051005 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM)
Intarcia Therapeutics, Inc
Hayward, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions